On The Horizon - AZR-MD-001

Azura Ophthalmics is researching a new therapeutic agent, AZR-MD-001, in patients with Meibomian Gland Dysfunction. In an initial multicenter, double-masked, vehicle-controlled, randomized, parallel group clinical trial patients with meibomian gland dysfunction who were treated with an ointment containing selenium sulfide experienced improvement in dry eye symptoms,

Over three months the changes to meibomian gland secretions and symptoms was compared. 85.7% of patients in the AZR 1% group had improvements.

“AZR-MD-001 has potential to be the first effective pharmacotherapy specifically intended for MGD,” Dr Laura Downie.

NOTE: The author has no financial interest in any products mention in this article.